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Abstract 
Type 1 diabetes mellitus (T1D) is an autoimmune disorder where T lymphocytes damage the 
islet beta cells but B lymphocytes also play an important role. Although changes in 
peripheral B cell phenotype have been observed, little is known about the B cells that 
secrete the autoantibodies. 
We developed a sensitive B cell enzyme-linked immunospot assay (ELISpot assay) to detect 
individual B cell antibody responses to glutamic acid decarboxylase (GAD) and islet antigen-
2 (IA-2). 
We found that even healthy donors have B cells that secrete antibodies in response to GAD 
and IA-2 in the ELISpot.  There was increased B cell reactivity to autoantigens in the 
peripheral blood of individuals with newly-diagnosed, but not long-standing, type 1 
diabetes.  However, no correlation with serum autoantibody levels was found, indicating 
that additional factors such as antigen affinity or exposure to antigens in vivo are required 
for antibody secretion, and that even healthy donors have potentially autoreactive B cells. 
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1. Introduction  
 
Type 1 diabetes (TID) is an immune-mediated disease that occurs in genetically susceptible 
individuals, with risk modified by the environment.  Although T cells play a central role in 
islet beta cell damage, B cells clearly are also important in pathogenic processes. 
Autoantibodies secreted by B cells provide an early indication of autoimmunity. The risk of 
developing type 1 diabetes is indicated by the presence of autoantibodies against islet 
antigens such as insulin, glutamic acid decarboxylase (GAD), islet antigen-2 (IA-2) and the 
zinc transporter (ZnT8) [1].  High serum antibody titres of one or more autoantibodies are 
often present upon initial diagnosis of T1D. Healthy individuals can have one or two 
autoantibodies present at a lower titre and may not proceed to develop T1D. Anti-GAD 
antibodies can remain detectable for many years whereas anti-IA-2 or ZnT8 antibodies tend 
to decrease rapidly after diagnosis [2]. Although these serum autoantibody-titres are useful 
markers of disease onset, they cannot be used as markers of ongoing autoimmunity after 
diagnosis and do not provide information regarding the cells that produce them.  
B cells are found in the pancreas of individuals with type 1 diabetes [3, 4], and B cell 
depletion with rituximab can slow the loss of insulin production [5]. We, and others, have 
demonstrated that changes in the phenotype of peripheral B cells are also observed in 
people with type 1 diabetes. These changes included a decrease in CXCR3, B220, CD24, 
CD95, BAFFR and TACI expression [6-8]. In addition, decreased percentages of CD24++CD38++ 
B cells (thought to be regulatory B cells) [9],  increased plasmablasts [6], increased 
frequencies of marginal zone CD19+CD21+CD23− B cells and decreased frequencies of 
regulatory CD1d+CD5+CD19+ and follicular CD19+CD21−CD23+ B cells [10] have all been 
observed in individuals with type 1 diabetes.   
In terms of antigen specificity, “insulin binding” B cells have been investigated for 
phenotype and frequency in the peripheral blood. These were found to be predominantly 
naïve anergic cells in healthy donors, whereas in people with newly-diagnosed diabetes they 
were lost, suggesting that they had trafficked to the pancreas [11]. Long-term antibody 
titres are maintained by long-lived antibody-secreting plasma B cells, and memory B cells 
can also differentiate into plasma cells to replenish the pool. Memory B cells are unique in 
function and phenotype compared to other types of B cells. They remain quiescent for a 
long duration but rapidly respond on re-exposure to antigen and can quickly differentiate 
into plasma cells to produce high-affinity antibodies to eliminate pathogens not removed by 
existing circulating antibodies [12-15]. In type 1 diabetes, it is not known whether there are 
autoreactive memory B cells in the circulation, which could contribute to the replenishment 
of the autoantibody-producing plasma cell pool.  
To investigate whether circulating B cells recognise autoantigens and produce IgG auto-
antibodies, we used a polyclonal activation protocol to stimulate memory B cells from the 
peripheral blood, before determining their ability to secrete GAD- and IA-2-targeting IgG 
antibodies using ELISpot analysis. 
 
 
 
 
2. Methods  
2.1 Study subjects 
PBMCs were isolated from the peripheral blood of individuals with newly diagnosed, ND (<1 
year, n=20, female=7, mean age: 30 years (range: 18-47 years), mean disease duration 0.4 
years (range 0.1-1.0 years)), and long-standing, LS (>3 years) type 1 diabetes (n=20, female= 
11, mean age: 34 years (range 18-48 years), mean disease duration: 17.7 years (range: 3-36 
years )), as well as age- and sex-matched healthy donors, HD (n=35, female= 12, mean age: 
33 years (range 18-48 years)). Type 1 diabetes was diagnosed according to criteria 
established by the American Diabetes Association [10], and insulin treatment was 
commenced within one month of diagnosis.  The details of individuals studied are shown in 
Supplementary Table A1, A2 and A3. 
This study was approved by the South East Wales Research Ethics Committee and 
conducted in accordance with the principles of Good Clinical Practice established by the 
International Council for Harmonization/World Health Organization. All subjects provided 
written informed consent prior to enrolment as mandated by the Declaration of Helsinki.  
2.2 HLA class II genotyping 
Genomic DNA was extracted from whole blood samples collected in 
ethylenediaminetetraacetic acid (EDTA). HLA-DRB alleles were resolved using polymerase 
chain reactions with sequence-specific primers [16] and are listed in Supplementary Table 
A2 and A3.  
 
2.3 Blood samples 
Serum samples were separated on the day of collection and stored in 1.5 ml Eppendorf 
tubes at -20oC before levels of serum antibodies were analysed in batches.  Serum 
autoantibodies specific for GAD and IA-2 were quantified by ELISA (RSR Limited, Cardiff, UK). 
Positive thresholds were set at 5 U/mL and 7.5 U/mL respectively. Peripheral blood 
mononuclear cells (PBMCs) were isolated from heparinized samples of whole blood via 
density gradient centrifugation over Lymphoprep (Stem Cell Technologies).  
 
2.4 Cell culture 
Freshly isolated PBMCs were cultured for 5-7 days, 37oC at a cell concentration of 0.5x106 
/ml in RPMI/10% heat inactivated human AB serum/penicillin/streptomycin/ L-glutamine, 
0.001% v/v pokeweed mitogen extract (gift from Prof. Shane Crotty, La Jolla Institute for 
Allergy & Immunology), 0.1µg/ml (2.4nM) protein A soluble from Staphylococcus aureus 
Cowan strain (SAC) (Sigma) and 4µg/ml (0.52µM) CpG-ODN 2006 (Keck Foundation 
Biotechnology Resource Laboratory, Yale University, New Haven). 
2.5 ELISpot 
Multiscreen-IP 96 separation system, 0.45µm Immobilin-P PVDF membrane (Merck 
Millipore) plates were pre-wetted with 70% molecular grade ethanol (Sigma), then washed 
and coated with either PBS, 0.5µg/ml goat antihuman IgG (Newmarket scientific) (as a 
positive control, data not shown), or recombinant human antigens (RSR Limited, Cardiff, UK) 
overnight at 4˚C. Antigen concentrations were as follows: rhGAD65 used at 0.4µg/ml 
(6.2nM), 0.8 µg/ml (12.3nM) or 1.6µg/ml (24.6nM); rhIA-2 intracellular fragment (aa 604-
979) (RSR Limited, Cardiff UK) used at 0.4µg/ml (8.7nM), 0.8 µg/ml (17.4 nM) or 1.6µg/ml 
(34.8nM).  Plates were then washed and blocked with RPMI 10% heat inactivated foetal 
bovine serum (HI-FBS), overnight at 4˚C. 
The following day, blocking solution was removed and cells were washed in RPMI 10% HI-
FBS, resuspended at 4x106 cells/ml and 100μl was placed in each well (4x105/well). For the 
IgG positive control cells were resuspended at 5x104/ml and 100μl was placed in each well 
(5x103/well).  Plates were incubated for 5 hours at 37˚C, then washed with PBS/0.05% 
Tween 20, then incubated overnight at 4˚C with goat-anti-human IgG Fc biotin antibody 
(eBioscience) at 0.5µg/ml in PBS/0.05% Tween 20/5% HI-FBS. 
The following day, the plates were washed and developed with ExtrAvidin (Sigma) diluted 
1/5000 in PBS/0.05% Tween 20/ 5% HI-FBS, followed by BCIP/NBT substrate (Sigma). Plates 
were then washed and dried overnight before being read on a BIO-SYS GmbH Bioreader 
4000 using a minimum spot size of 30µm. All bioreader images were checked manually to 
ensure spots were correctly identified. The background number of spots, produced in wells 
coated with PBS, was subtracted from the counts for each antigen-coated well. A minimum 
of 6 wells were counted and averaged for each condition.  All individuals responded to the 
positive control stimulation. 
2.6 Statistics  
Data were analysed using Graphpad Prism 5 and R v3.4.1 for the plot matrix (ggplot2 and 
GGally packages, ggpairs plot). ELISpots were analysed using a Mann Whitney test to 
compare between two groups and a Kruskal-Wallis test, followed by Dunn’s multiple 
comparison for comparison between three groups, as the data were not normally 
distributed.  
3. Results  
We used a range of antigen concentrations to coat the ELISpot plates. Healthy donors (HD) 
exhibited a response to both GAD and IA-2 above the background level of spots. A dose 
titration was observed, with the effect dependent on the coating concentration for both 
antigens (Fig 1A, D). After the background levels of spots were subtracted, the median 
number of spots (from 400,000 cells) was 5.5 at 0.4µg/ml (6.15nM) GAD and 15.9 at 
0.8µg/ml (12.3nM) GAD (p<0.005). For IA-2, the median number of spots (from 400,000 
cells) was 4.2 at 0.4µg/ml (8.7nM) IA-2 and 10.5 at 0.8µg/ml (17.4nM) IA-2 (p<0.05). 
Compared to healthy donors (HD), the newly diagnosed (ND) cohort had a significantly 
higher response to GAD at both 0.4µg/ml (6.2nM) (HD 5.5 spots, ND 16.8 spots, p<0.01), 
and 0.8µg/ml (12.3nM) (HD 15.9 spots, ND 36 spots p<0.05), (Fig 1B, C). The long-standing 
(LS) cohort was not significantly different to the healthy donors (median 14.8 spots at GAD 
0.4µg/ml (6.15nM) and 33.2 at GAD 0.8µg/ml (12.3nM)). The spot counts were not normally 
distributed and appeared to have a bimodal distribution.  
In response to IA-2, the newly diagnosed (ND) cohort had increased spots compared to the 
healthy donors (HD) at 0.8µg/ml (17.4nM) (HD 10.5 spots, ND 28 spots, p<0.05), but not 
0.4µg/ml (8.7nM) (HD 3.7 spots, ND 10.4 spots), (Fig 1E, F). Again, long-standing (LS) donors 
were not significantly different at either concentration of antigen (median 6.9 spots at IA-2 
0.4µg/ml (8.7nM) and 19.6 at IA-2 0.8µg/ml (17.4nM)). 
We compared spots in the GAD and IA-2 0.8µg/ml (12.3nM and 17.4nM respectively) 
ELISpots, with GAD and IA-2 antibody titres. The concentration of antigen was chosen 
because there was a significant difference in the number of spots seen between healthy 
donors and newly diagnosed donors at this coating concentration. In the newly diagnosed 
and long-standing cohorts, serum titres of GAD or IA-2 autoantibodies were not correlated 
with spots produced in the respective GAD or IA-2 0.8ug/ml ELISpot assay, with high ELISpot 
counts occurring even when antibody titres were below the cut-off for a positive antibody 
result (GAD 5 U/ml, IA-2 7.5 U/ml) [17]. Indeed for both, there was a non-significant 
negative correlation between GAD antibody and GAD ELISpot (LS r= -0.191, ND r =-0.422) 
and for the newly diagnosed cohort between IA-2 antibody titre and IA-2 ELISpot (LS r= 
0.221, ND r =-0.435) (Fig 2). However, GAD and IA-2 antibody titres were weakly correlated 
for both of these cohorts (LS r= 0.164, ND r =0.271) consonant with findings of others [18].  
There was no correlation or differences found related to HLA type (supplementary table A3). 
 
4. Discussion  
Here we have demonstrated that ELISpots can be used to detect B cell responses to 
autoantigens in T1D. Moreover, we showed that whilst B cells from healthy donors and 
people with long-standing diabetes could secrete antibody in response to diabetic 
autoantigens, the increase in the number of autoreactive B cells was only significant in the 
PBMCs of people with newly-diagnosed diabetes.  
B cell responses in type 1 diabetes are normally assessed by quantification of serum 
antibodies, produced by plasma cells. However, this does not provide a measurement of the 
memory B cells that may be circulating but not secreting antibodies [19, 20]. Whilst B cell 
ELISpots have been widely used to detect vaccine and infectious disease responses, the few 
reported incidences of their use in autoimmune disease relate to multiple sclerosis [21], SLE 
[22] and pemphigus vulgaris [23], showing that autoreactive B cells are detectable by 
ELISpot. 
 We used a method of stimulating memory B cells using Pokeweed mitogen (PWM) 
combined with S. aureus (Cowan strain, SAC) and a CpG oligonucleotide (ODN-2006), 
adapted from the method used by Crotty et al [20]. This pre-stimulation induces memory B 
cells to differentiate into antibody secreting cells [24]. Crotty and colleagues [20] used this 
method to identify memory B cells with a response to vaccines, and demonstrated that the 
responding cells in their assay were CD27+. 
It has been found that many autoreactive B cells in healthy donors are anergic with a 
mature naïve (CD19 + CD27−IgD+) phenotype and low affinity for autoantigens. At the onset 
of autoimmune diseases including T1D, SLE and autoimmune thyroid disease [25] [26], these 
anergic, naïve B cells are transiently lost from the peripheral blood suggesting that they may 
have become activated and travelled to the site of autoimmunity. However, it has also been 
demonstrated that a substantial minority of insulin-binding cells in the peripheral blood of 
both healthy donors and people with diabetes are CD27+ memory B cells [11]. Indeed 
insulin-binding cells are found in all major B cell compartments, although their affinity for 
insulin may be very low, with high-affinity insulin binding cells found only in the anergic 
naïve subset [11, 26].  
Our data demonstrated that even healthy donors had B cells that could produce antibodies 
in response to GAD and IA-2 in a concentration-dependent manner. The polyclonal pre-
stimulation may overcome anergy present in these B cells, and the ELISpot will potentially 
detect B cells with receptors that have a range of affinity of antigen binding. We therefore 
hypothesise that the antigen-specific antibody secreting cells from the healthy donors may 
be either anergic in vivo and/or have very low affinity for the autoantigens, such that at 
physiological antigen concentrations they are not induced to secrete antibodies. However, it 
is likely that they exist in the peripheral blood as CD27+ memory cells, as these are the cells 
that are activated by the pre-stimulation, rather than mature naïve B cells.  
The fact that people with long-standing type 1 diabetes did not have significantly more 
antigen-specific antibody secreting cells than healthy donors was perhaps not surprising as 
it is known that levels of serum autoantibodies decline in people with long-standing 
diabetes [27]. T cell responses to auto-antigenic peptide epitopes also decline in people with 
long-standing diabetes to levels observed in people with no type 1 diabetes [28]. 
We observed that people with newly diagnosed type 1 diabetes had significantly more 
antigen-specific antibody secreting cells than healthy donors. This novel finding suggests 
that there are more circulating B cells in the peripheral blood capable of producing 
autoantibodies, and potentially that there are stimuli present that induce these to produce 
the autoantibodies. 
In summary, we found that B cells that secrete autoantibodies to specific-antigens are more 
abundant in people newly diagnosed with type 1 diabetes, and that those B cells can remain 
for many years in people considered long-standing. More interestingly, they are also present 
in people with no history of type 1 diabetes. Further experiments will be required to 
elucidate which B cell subsets produce these antibodies and whether the antibodies from 
healthy donors and people with diabetes have equivalent affinities for autoantigens.  
 
Figure 1. Healthy donors and people with type 1 diabetes have B cells in the peripheral 
blood that can produce autoantibodies to GAD and IA-2. A. Titration of GAD coating 
concentration: Spot-forming response of healthy donor PBMCs to indicated GAD coating 
concentration (with the background response to PBS coating subtracted). B. Spot forming 
response of healthy donors and people with ND and LS type 1 diabetes to 0.4µg/ml 
(6.15nM) GAD coating solution (with the background response to PBS coating subtracted). C 
Spot forming response of healthy donors and people with ND and LS type 1 diabetes to 
0.8µg/ml (12.3nM) GAD coating solution (with the background response to PBS coating 
subtracted). D. Titration of IA-2 coating concentration: Spot-forming response of healthy 
donor PBMCs to indicated IA-2 coating concentration (with the background response to PBS 
coating subtracted). E. Spot forming response of HDs and people with ND and LS type 1 
diabetes to 0.4µg/ml (8.7nM) IA-2 coating solution (with the background response to PBS 
coating subtracted). F. Spot forming response of HDs and people with ND and LS type 1 
diabetes to 0.8µg/ml (17.4nM) IA-2 coating solution (with the background response to PBS 
coating subtracted). * p<0.05, **p<0.01, ***p<0.005 (A, D; Mann Whitney test. B, C, E, F; 
Kruskal-Wallis test, followed by Dunn’s multiple comparison). Lines represent the median. 
Figure 2. The number of antigen-specific antibody secreting cells is not correlated to serum 
antibody titres. Plot matrix of serum antibody concentrations (GAD, IA-2, log values) and 
PBMC responses in ELISpot to GAD 0.8 µg/ml (12.3nM) (PBS background subtracted) and IA-
2 0.8 µg/ml (17.4nM) (PBS background subtracted). On the lower left side: scatterplots of 
the variables plotted against each other as indicated on the axes. Correlation (r value) for 
the variables as indicated on the axes are to the right of each graph. Diagonally: Histograms 
showing the distribution of the variables. Pink- healthy donor. Green- LS type 1 diabetes. 
Blue- ND type 1 diabetes. Black (r value only) - all samples.  
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